A randomized, double-blind phase II trial to assess the efficacy and safety of bicalutamide (Casodex ) associated to ZD6474 (Zactima) [vandetanib] or to placebo in patients with castration-refractory metastatic prostate cancer without any clinical symptom related to disease progression.

Trial Profile

A randomized, double-blind phase II trial to assess the efficacy and safety of bicalutamide (Casodex ) associated to ZD6474 (Zactima) [vandetanib] or to placebo in patients with castration-refractory metastatic prostate cancer without any clinical symptom related to disease progression.

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Dec 2016

At a glance

  • Drugs Vandetanib (Primary) ; Bicalutamide
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 13 Jul 2012 Actual end date (Jul 2011) added as reported by ClinicalTrials.gov.
    • 13 Jul 2011 Planned end date changed from 1 Jun 2011 to 1 Jul 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top